Enanta Announces High SVR Rates with AbbVie’s VIEKIRAX® + EXVIERA® Regardless of the Presence of Resistance-Associated Variants Prior to Treatment in Genotype 1 Chronic Hepatitis C Patients (Enanta Pharmaceuticals Inc)

(Source: Enanta Pharmaceuticals Inc) 100 percent of genotype 1b (GT1b) patients who received VIEKIRAX + EXVIERA without ribavirin for 12 weeks, achieved SVRin a post-hoc analysis,regardless of whether baseline NS5A RAVs were present 97 percent of genotype 1a (GT1a) patients, with or without baseline NS5A RAVs, who received the regimen with ribavirin achieved SVR WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 14, 2016-- Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced today data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV)...